Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.33 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.32 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL5016617 | 0.94 | — | — | |
| SCHEMBL10918913 | 0.88 | CA4 (0.30) | CA4FAHD1 | |
| SCHEMBL5886409 | 0.87 | CA4 (0.38) | CA4FAHD1CA1 | |
| Potassium Ion SCHEMBL16910245 | 0.80 | CA4 (0.38) | CA4FAHD1 | |
| SCHEMBL11600646 | 0.77 | — | — | |
| SCHEMBL5367506 | 0.75 | CA4 (0.33) | CA4FAHD1CA1 | |
| SCHEMBL11485145 | 0.73 | CA4 (0.38) | CA4FAHD1CA1 | |
| SCHEMBL9841028 | 0.73 | — | — | |
| SCHEMBL11580119 | 0.73 | CA4 (0.32) | CA4FAHD1CA1 | |
| SCHEMBL31349189 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4238346-A | ALKALI METAL ALUMINOSILICATES | MIZUSAWA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1980-12-09 | — | — | US | claimed |
| US-3985669-A | Detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1976-10-12 | — | — | US | claimed |
| US-7129368-B2 | Platinum carboxylate anticancer compounds | SONUS PHARMACEUTICALS, INC. (US) | 2006-10-31 | — | — | US | disclosed |
| WO-2005090372-A2 | PLATINUM CARBOXYLATE ANTICANCER COMPOUNDS | SONUS PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050209321-A1 | Platinum carboxylate anticancer compounds | SONUS PHARMACEUTICALS, INC. | 2005-09-22 | — | — | US | disclosed |
| US-4238346-A | ALKALI METAL ALUMINOSILICATES | MIZUSAWA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1980-12-09 | — | — | US | disclosed |
| US-4219535-A | Alkali metal aluminosilicate detergent builder | MIZUSAWA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1980-08-26 | — | — | US | disclosed |
| US-4166039-A | SPRAY DRYING, INCORPORATING A NONIONIC SURFACTANT WITH A KALINITE OR BENTONITE LCAY | THE PROCTOR & GAMBLE COMPANY (US) | 1979-08-28 | — | — | US | disclosed |
| US-4102977-A | ACID TREATING SMECTITE CLAY | MIZUSAWA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1978-07-25 | — | — | US | disclosed |
| US-3983078-A | Oil removal detergent compositions | THE PROCTER & GAMBLE COMPANY (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209321-A1 | Platinum carboxylate anticancer compounds | TP53, PCNA, MCL1 | CA4 1103/4885CA1 533/4885FAHD1 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.